|
1
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Gondos A and Pulte D: Recent
major improvement in long-term survival of younger patients with
multiple myeloma. Blood. 111:2521–2526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alexanian R, Delasalle K, Wang M, Thomas S
and Weber D: Curability of multiple myeloma. Bone Marrow Res.
2012:9164792012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Attal M, Harousseau JL, Leyvraz S, Doyen
C, Hulin C, Benboubker L, Agha Yakoub I, Bourhis JH, Garderet L,
Pegourie B, et al: Maintenance therapy with thalidomide improves
survival in patients with multiple myeloma. Blood. 108:3289–3294.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgan GJ, Gregory WM, Davies FE, Bell SE,
Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, et al:
The role of maintenance thalidomide therapy in multiple myeloma:
MRC Myeloma IX results and meta-analysis. Blood. 119:7–15. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McCarthy PL, Owzar K, Hofmeister CC, Hurd
DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ,
Vij R, et al: Lenalidomide after stem-cell transplantation for
multiple myeloma. N Engl J Med. 366:1770–1781. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Attal M, Lauwers-Cances V, Marit G,
Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L,
Garderet L, et al: Lenalidomide maintenance after stem-cell
transplantation for multiple myeloma. N Engl J Med. 366:1782–1791.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Richardson PG, Schlossman RL, Weller E,
Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D,
Kelly K, et al: Immunomodulatory drug CC-5013 overcomes drug
resistance and is well tolerated in patients with relapsed multiple
myeloma. Blood. 100:3063–3067. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Durie BG, Harousseau JL, Miguel JS, Bladé
J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J,
Sonneveld P, et al: International uniform response criteria for
multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Quigley J, Pepe M and Fisher L:
Continual reassessment method: A practical design for phase 1
clinical trials in cancer. Biometrics. 46:33–48. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishizuka N and Morita S: Practical
implementation of the continual reassessment method. Handbook of
Statistics in Clinical Oncology (2nd). 2006.
|
|
12
|
Palumbo A, Mina R, Cerrato C and Cavallo
F: Role of consolidation/maintenance therapy in multiple myeloma.
Clin Lymphoma Myeloma Leuk. 13(Suppl 2): S349–S354. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abidi MH, Gul Z, Abrams J, Ayash L, Deol
A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z,
Ratanatharathorn V, et al: Phase I trial of bortezomib during
maintenance phase after high dose melphalan and autologous stem
cell transplantation in patients with multiple myeloma. J
Chemother. 24:167–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spencer A, Prince HM, Roberts AW, Prosser
IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J and
Kennedy N: Consolidation therapy with low-dose thalidomide and
prednisolone prolongs the survival of multiple myeloma patients
undergoing a single autologous stem-cell transplantation procedure.
J Clin Oncol. 27:1788–1793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lokhorst HM, van der Holt B, Zweegman S,
Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans
P, Schaafsma R, de Weerdt O, et al: A randomized phase 3 study on
the effect of thalidomide combined with adriamycin, dexamethasone,
and high-dose melphalan, followed by thalidomide maintenance in
patients with multiple myeloma. Blood. 115:1113–1120. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sonneveld P, Schmidt-Wolf IG, van der Holt
B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E,
Broyl A, Blau IW, et al: Bortezomib induction and maintenance
treatment in patients with newly diagnosed multiple myeloma:
Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin
Oncol. 30:2946–2955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palumbo A, Cavallo F, Gay F, Di Raimondo
F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C,
Ribakovsky E, et al: Autologous transplantation and maintenance
therapy in multiple myeloma. N Engl J Med. 371:895–905. 2014.
View Article : Google Scholar : PubMed/NCBI
|
